

Name	Ji Eun Jang
Current Position & Affiliation	Associate professor (Division of Hematology), Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Country	South Korea
Major Field	Hemato-oncology Hematopoietic stem cell transplantation

Educational Background

2001.3-2003.2	Premedicine, Yonsei University College of Science, Seoul, South Korea
2007.2	M.D., Yonsei University College of Medicine, Seoul, South Korea
2019.2	PH.D., Yonsei University College of Medicine, Seoul, South Korea

Professional Experience

2013.3–2016.2: Fellowship (Division of Hematology), Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

2016.3-2017.2: Clinical assistant professor (Division of Hematology), Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

2017.3- 2021.2: Assistant professor (Division of Hematology), Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

2023.3-2025.2: Visiting Scientist, Dana Faber Cancer Institute, Harvard University, USA

2022.3- current: Associate professor (Division of Hematology), Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

Other Experience and Professional Memberships

Present Member of the American Society of Hematology
 Present Member of the Korean Society of Hematology
 Present Member of the Korean Society of Hematopoietic Stem Cell Transplantation
 Present Member of the Korean Society of Internal Medicine

Main Scientific Publications

DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation / **Cancers** / 2023, 15, 745

Development of a Next-Generation Sequencing-Based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia / **Annals of Laboratory Medicine** / 2023

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells / **Experimental Hematology and Oncology** /2021 Apr;10:28

PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells / **Journal of Experimental & Clinical Cancer Research** / 2020 Apr; 39:e66

Early Cytomegalovirus Reactivation and Expansion of CD56brightCD16dim/DNAM1+ Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia / **Biology of Blood and Marrow Transplantation** /2019 Oct;25:2070-2078